Navigation Links
Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting

nd demonstrated that the electroporation-enhanced immune responses to a hepatitis C DNA vaccine were capable of eliminating all liver cells that produced a model hepatitis C virus gene, simulating a potential cure of hepatitis C infection. Vaccination by methods not employing Inovio's technology were less or not effective.

Two other Inovio presentations reported electroporation device innovations including the Elgen 1000 system and a single-needle device. The Elgen 1000 system, which recently received CE marking, consists of an advanced pulse generator and a two-needle DNA injector that delivers the genes and electroporation pulses in a single step. The pulse generator allows flexible programming of pulse and injection parameters via a flash card operated personal computer, as well as comprehensive recording and storage of electroporation and patient data. The single needle device, in early development, allows injection of the DNA and electroporation with a single needle resembling a normal injection needle and applies pulses of lower voltage than those delivered by presently used devices, thus reducing the electrical sensation experienced by the patient.

"We are pleased with the performance of our DNA delivery technology in advanced preclinical studies. Together with our continuing innovations in electroporation devices, our technology may be able to make critical contributions to the development of novel, effective vaccines for the treatment or prevention of major life-threatening infectious diseases," said Dr. Avtar Dhillon, Inovio's president and CEO.

About Inovio's Immunotherapy Products

DNA-based immunotherapy products have the potential to by-pass inherent scientific obstacles of conventional vaccines that prevent their development for cancer and chronic infectious diseases such as HIV and hepatitis C. Pre-clinical data has indicated the potential ability of Inovio's technologies to safely and effectively deliver and significantly
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
3. Inovio: DNA delivery technology shows positive human results
4. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
5. Inovio Biomedicals DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
9. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Post Your Comments:
(Date:12/14/2009)... 14 In response to an ... in which the Agency recommended that healthcare facilities ... sterile processing system, hospitals throughout the U.S. are ... to that product. According to the FDA, STERIS ... that may affect the safety or the effectiveness ...
(Date:12/14/2009)... -- Following is a statement by Linda A. ... Association (CHPA), regarding today,s release of the National ... survey: ,, "Findings released today on this year,s ... for continued efforts to educate and empower parents ... their teens about medicine abuse. The Consumer Healthcare ...
(Date:12/14/2009)... The board of directors of Eli Lilly ... a dividend for the first quarter of 2010 of ... ,, The dividend is payable March 10, 2010 to ... ,, February 12, 2010. ,, Lilly, a leading ... products by applying the latest research from its own ...
Breaking Medicine Technology:ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 2Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 3Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 1Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 2Protein handlers should be effective treatment target for cancer and Alzheimers 9501 1Protein handlers should be effective treatment target for cancer and Alzheimers 9501 2Protein handlers should be effective treatment target for cancer and Alzheimers 9501 3America Takes on the Challenge to Fight Obesity 53865 1America Takes on the Challenge to Fight Obesity 53865 2America Takes on the Challenge to Fight Obesity 53865 3America Takes on the Challenge to Fight Obesity 53865 4
... lowest dose groups show dose-dependent PSA ... declines to date in all patients - - ... SAN FRANCISCO, Nov. 5 Medivation, Inc.,(Nasdaq: MDVN ) today ... levels of prostate specific,antigen (PSA), a marker of tumor growth, in the ...
... non-responders to previous interferon-based therapy -, - SVR results in ... non- responders, with less frequent dosing -, - ... American Association for the Study of Liver Diseases ... (AASLD) -, ROCKVILLE, Ma., Nov. 5 ...
Other Medicine Technology:Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 2Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 3Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
(Date:12/14/2009)... are higher than generally thought, raising concerns about increased risk for ... California, San Francisco (UCSF) imaging specialists. , ... ... common CT procedures vary widely and are higher than generally thought, ... study led by University of California, San Francisco (UCSF) ...
(Date:12/14/2009)... Tide of Tens of Thousands of New Chronic ... Legislation approved by Congress providing for ... in helping to reduce tens of thousands of ... the United States, the National Viral Hepatitis ... was included in the FY 2010 Consolidated Appropriations ...
(Date:12/14/2009)... 2009, the United States Court of Appeals, Tenth Circuit, ... are "plans" and therefore subject to federal jurisdiction. (US ... that contracts issued by insurance companies may be subject ... US vs. Frost is the first case an ... "plan," because, as the government claimed in this case, ...
(Date:12/14/2009)... linked to scans performed in 2007 , , MONDAY, Dec. ... patients to far more radiation than previously thought and in ... year, two new studies claim. , Based on the findings, ... of Internal Medicine , the study authors, joined by ... clinicians to limit radiation exposure to patients. , "CT has ...
(Date:12/14/2009)... of scientists from the UC San Diego School of ... protein switch that helps prevent liver damage, including inflammation, ... understanding of how the protein, TAK1, works could lead ... and cancer. , "TAK1 appears to be a ... MD, professor of medicine and Dean of the UC ...
Breaking Medicine News(10 mins):Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Scientists uncover protective mechanism against liver cancer 2
... characterization of renal transplant patients being weaned ... ... Data developed by Cylex in,conjunction with the University of Pittsburgh ... Canada, suggest,that cell-mediated immunity and anti-HLA antibody assays may be independent,measures ...
... For the past 70 years the treatment of ... therapy. That is, the suppression of circulating testosterone ... castration (orchiectomy) or medical castration with testosterone-blocking drugs. While ... a cure, as inevitably the cancer becomes resistant to ...
... time with pancreatic, kidney cancers, respectively , , ... with pancreatic cancer -- which historically carries a ... when the cancer drug Gemzar was used after ... 15 percent of pancreatic cancer patients are even ...
... progression-free survival, study finds , , SATURDAY, May 31 ... chemotherapy lengthened progression-free survival in women with advanced ... have found that adding Avastin (bevacizumab) to the ... breast cancer actually doubled progression-free survival. , Avastin ...
... likely to have diminished ovarian reserve producing viable ... News) -- Chemotherapy may reduce fertility in breast ... researchers at Boston,s Dana-Farber Cancer Institute. , They ... chemotherapy following surgery were more likely than women ...
... and cold medication use in young children has been ... several deaths, leading the FDA to recommend against their ... these concerns about safety and efficacy, there has been ... use in very young children. Now, a new study ...
Other Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 2Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 3Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3Health News:Chemo May Limit Fertility in Breast Cancer Survivors 2Health News:Study examines cold medication use in young children 2
Round knurled handle. Overall length 130 mm....
Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
DIX foreign body spud 4 3/4 inches, 1.7 x 15 mm blade....
Foreign body spud very thin, lightly curved and rounded tip....
Medicine Products: